Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Chronic Idiopathic Constipation (CIC): later-stage trial registry

2 of 3 indexed Chronic Idiopathic Constipation (CIC) trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Chronic Idiopathic Constipation (CIC): 3 US clinical trials tracked, 2 recruiting.

Chronic Idiopathic Constipation (CIC) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 2 of these trials.

Enrollment posture brief

Registry condition chronic-idiopathic-constipation-cic

OPEN 2 | RECR 67% | LATE 1 | EARLY 0 | RANK #5209 | SPON 2

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Chronic Idiopathic Const (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation (CIC) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Idiopathic Constipation (CIC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Idiopathic Constipation (CIC) is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Takeda 2 trials
Ardelyx 1 trials

Named interventions

Most-linked intervention names on Chronic Idiopathic Constipation (CIC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

No Intervention Other
2 trials
Tenapanor 50 mg BID Drug
1 trials
Tenapanor 25 mg BID Drug
1 trials
Tenapanor 5 mg BID Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Chronic Idiopathic Constipation (CIC) trials. A trial with sites in several states counts in each.

California 3 trials
Georgia 1 trials
Florida 1 trials
Colorado 1 trials
Arizona 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Idiopathic Constipation (CIC) page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Chronic Idiopathic Constipation (CIC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Takeda sponsors the most Chronic Idiopathic Constipation (CIC) trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Idiopathic Constipation (CIC) condition card totals 3 registered trials; most-linked intervention No Intervention; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.